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Abstract
This study aims to clarify the effects of chicken liver hydrolysates (CLHs) on long-term high-fat diet (HFD)-induced
insulin resistance (IR) and hepatosteatosis in mice. In vitro, the 400 mM oleic acid (OA)-added medium successfully
stimulated the cellular steatosis on FL83B cells, and the cellular steatosis was attenuated ( p < 0.05) by supplementing
with CLHs (4 mg/L). In vivo, the effects of CLHs on IR and hepatosteatosis development were tested in 20-week HFD-fed
mice. HFD-induced increases in ﬁnal body weight, but body weight gains of mice were decreased ( p < 0.05) by supplementing CLHs. Elevated ( p < 0.05) serum aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline
phosphatase (ALP), free fatty acids (FFAs), triglyceride (TG), total cholesterol (TC), and fasted glucose values in HFD-fed
mice decreased ( p < 0.05) by supplementing CLHs. Both results of hepatic steatosis and ﬁbrotic scores also indicated the
retardation ( p < 0.05) of the hepatosteatosis in cotreated groups. Moreover, the CLH supplementation sustained ( p <
0.05) hepatic and peripheral insulin signal sensitivity in HFD-fed mice. CLH supplementation could ameliorate hepatic
lipid deposition, hepatic/peripheral IR in a long-term high-fat dietary habit, and also improve the universal glucose
homeostasis by upregulating hepatic and peripheral insulin sensitivities.
Keywords: Adipose tissue, Chicken-liver hydrolysates, Insulin resistance, Non-alcoholic fatty liver disease, Skeletal
muscle

1. Introduction

W

ithin decades, broilers have become one
of the most acceptable chicken sources
compared to local chicken breeds in Taiwan.
Their livers are one of the major by-products
during the slaughtering process. Generally, their
livers are regarded as useless and inexpensive
because of their restricted usage. However, livers
contain many nutrients, such as proteins, minerals, etc. Thus, a functional ingredient developed
from broiler livers may be a practical and potential direction to reduce a handling cost in poultry
industry. According to the Council of Agriculture,

Executive Yuan, Taiwan, approximately 240.17
million broilers were slaughtered (364,164 metric
tons) in 2019 [1]. A liver is approximately 2.5% (w/
w) weight in slaughtered broilers. Hence, the
annual yield of broiler livers is about 9,000 m.t. in
Taiwan. In the previous study, lipogenic gene
expressions were signiﬁcantly downregulated by
supplementing with chicken-liver hydrolysates
(CLHs); meanwhile, fatty-acid b oxidation were
upregulated in high fat/cholesterol diet-fed
hamsters supplemented with CLHs [2]. Lin et al.
also reported that CLH supplementation could
ameliorate the lipid accumulation in livers of
alcoholic liquid-diet fed mice [3]. This
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hepatoprotection of CLHs against alcoholic
damage has been patented in the USA as well [4].
Annually, 4.2 million people die from diabetes
mellitus (DM) associated complications worldwide,
and 90% of them relate to type 2 DM (T2DM) [5].
Remarkably, more than 70% of T2DM patients are
diagnosed with non-alcoholic fatty liver disease
(NAFLD), which means a high association between
them [6, 7]. Furthermore, it is suggested that NAFLD
patients should be screened for T2DM [8]. Hence,
the studies on delaying IR occurrence or improving
insulin sensitivity are valuable to NAFLD therapy
and T2DM. Recently, many food-origin compounds
and protein hydrolysates have been attracted
increasing attention due to its various bio-activities
[9-11]. Besides, lysine and glycine supplementation
sustain the blood glucose homeostasis in streptozotocin-induced hyperglycemic rats [12, 13]. For
hyperglycemia-induced hippocampus damages,
taurine could interfere with the advanced glycation
end products formation in vivo [14]. Notably, a dietary leucine effectively ameliorated the IR, tissue
inﬂammation, and hepatic lipid deposition;
furthermore, the synergistic effects of leucine and
some anti-diabetic agents have also been reported
[15]. Besides, previous studies reported that the
decreased hepatic lipid deposition against an
excessive energy intake could highly correlate to the
balance of triglyceride (TG) synthesis and energy
expenditure (fatty-acid b oxidation), which are both
modulated by up-streaming insulin signal, thus
emphasizing the crucial role of IR in NAFLD [16, 17].
Furthermore, diacylglycerol o-acyltransferase 2
(DGAT2), the last major enzyme for converting
diacylglycerol to triacylglycerol, and the mediumchain speciﬁc acyl-CoA dehydrogenase (ACADM),
a crucial enzyme in fatty-acid b oxidation, are suitable markers for screening the potential hepatoprotective agent against NAFLD.
Although the lipid-lowering effects of this
patented CLH has been proven via a hamster
model, the effects of this CLH on the insulin
signaling in a long-term high-fat dietary habit are
still not elucidated [2]. Chang et al. report that valproic acid enhances the hepatocyte steatosis via the
FL83B cell model. This cell model is suitable for
screening the effects on hepatocellular lipid accumulation [18]. Besides, unlike other animal models,
a long-term high-fat diet (HFD) feeding mimics both
the histopathology and pathogenesis of human
NAFLD and sheds light on the clinical application

[19]. In this study, we would like to clarify the lipidlowering mechanism of CLHs on hepatocytes via
the FL83B-cell model, as well as understand if CLHs
could improve the glycemic homeostasis in longterm HFD-fed mice. This study also aims to clarify
the hepatoprotective effects of CLHs on long-term
HFD-induced IR in mice. It offers important evidence to support its potential application to those
NAFLD patients with pre-diabetic symptoms in the
future.

2. Materials and methods
2.1. Materials and chemicals
All boiler livers (Arbor Acresþ) used in this study
were purchased from Charming Food Intl. Marketing Co., Ltd. (Taichung, Taiwan). This company has
the Certiﬁed Agricultural Standards (CAS) certiﬁcation in Taiwan. The transportation, storage, and
manufacture of chicken-liver hydrolysates (CLHs)
were conducted according to our patent [4]. All
other chemicals used in this study are of analytical
grade.
2.2. Nutritional composition and free amino-acid
proﬁle/Imidazole-ring dipeptides of CLHs
The nutritional composition of CLHs (i.e., water,
crude fat, crude protein, and ash contents) was
analyzed according to the assays of the Association
of Ofﬁcial Analytical Chemists (AOAC) [20]. For the
free amino-acid proﬁle, anserine and carnosine in
CLHs were analyzed according to a previous study
by using an Amino Acid Analyzer (Hitachi L8800
Amino Acid Analyzer, Hitachi High-Technologies
Co., Tokyo, Japan) in the Food Industry Research
and Development Institute (Hsinchu City, Taiwan)
[3].
2.3. FL83B cell culture
First, the culture method of FL83B cells was
slightly modiﬁed from the American Type Culture
Collection (ATCC) [18]. The short- and long-term
impacts of CLHs on the survivability of FL83B cells
in fetal bovine serum (FBS) containing culture system were determined (Fig. 1A), which could monitor
cellular morphology and growth condition
compared to those of ATCC. Survival assay (Cell
Counting Kit-8; Enzo Life Science, Inc., Farmingdale, NY, USA) and lactate dehydrogenase
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Fig. 1. Cell survival assay, lactic acid dehydrogenase (LDH) leakage assay, and lipid accumulated model of FL83B cells. (A) Cell survival assay under
different chicken liver hydrolysate (CLH) concentrations on 6- and 12-h incubation, respectively. (B) Cell survival and LDH leakage assays under
different CLH concentrations. (C) Cell survival and LDH leakage assays under different OA concentrations. (D) Lipid content analysis of FL83B cells
by using Nile red stain under different OA concentrations. The cultural conditions were as stated above in part (B). (E) Lipid stain by using Oil Red O
stain under different OA concentrations. (F) Lipid content analysis of FL83B cells treated with 400 mM OA and different CLH concentrations by using
Nile red stain. The data are given as mean ± SEM (n ¼ 6). In part (A), data bars without a common letter in 6-h and 12-h incubation, respectively,
indicate a signiﬁcant difference (p < 0.05). In contrast, the other data bars in each test parameter without a common letter indicate a signiﬁcant
difference ( p < 0.05). Each value of the treatment was adjusted with its control. In part (A), the assay was based on the ATCC's cultural guideline
(F12K medium with 10% FBS). Other assays were based on the F12K medium without FBS under 12-h incubation.

(LDH) leakage assay (LDH-Cytotoxicity Colorimetric Assay Kit II; BioVision Inc., Milpitas, CA,
USA) of cells were conducted according to the
commercial manuals, respectively. FL83B cells were
seeded in a 96-well plate (20,000 cells/well), incubated for 12 h to attach. The cell survival assay was
then taken after another 6- or 12-h incubation under
100 mL 10% FBS-contained media (0 to 4000 mg
CLHs/L). Next, 4 h before the harvest time point, the
10 mL CCK-8 was added. Final optical density values
were obtained via Synergy H1 Hybrid Reader (BioTek Instruments, Inc., Winooski, VT, USA).
2.4. Lipid accumulation model of the FL83B cell
According to the previous study, the lipid accumulation model was developed, and 12 h for oleic
acid (OA)-induction was proved to induce the

cellular steatosis successfully [18]. Thus, the 12 hincubation was chosen in the following procedure.
The CCK-8 cell survival assay and LDH leakage
analysis were conducted for determining the
optimal concentration of OA in the treating medium. The FL83B cells were seeded in a 96-well
plate (20,000 cells/well) and incubated for 12 h for
attachment both in CCK-8 and LDH assays. The cell
survival assay was taken after a 12 h incubation
under the 100 mL treating medium. 10 mL CCK-8
solution was added at 4 h before the harvest time
point. In LDH leakage analysis, the medium was
harvested and measured after a further 12 h incubation. Besides, both of the two experiments were
based on the F12K medium without FBS to elevate
the cellular accessibility of OA [18]. For visual
analysis, the procedure of Oil red O stain was conducted respectively. The FL83B cells were seeded in
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a 12-well plate (20,000 cells/well) and incubated for
12 h to attach. Next, the assay was taken after the
further 12-h incubation under the one mL treating
medium. The medium was based on the FBS free
F12K medium. 4% paraformaldehyde and Oil red O
solution (0.35 g in 100 mL 60% isopropanol) was
used to ﬁx and stain cells for 10 min, sequentially.
The magniﬁcation of all images was 200 . The
cellular lipids were illustrated in bright red in the
photos. The microscopic analysis was determined
via Olympus microscope (Olympus Co., Tokyo,
Japan) with Toup View 3.7 software (Toup Tek Co.,
LTD, Hangzhou, China). The Nile red stain method
was used (excitation: 485 nm, emission: 535 nm) [18].
FL83B cells were seeded in 20,000 cells per well of
96-well plate and incubated at 37  C, 5% CO2 for 12
h. All treating intervals were 12 h. All values were
adjusted with each ﬂuorescent intensity of Hoechst

stain (excitation: 350 nm, emission: 461 nm), indicating nuclei. The lipid content was calibrated with
those of the control group (0 mM OA).
2.5. Western blotting
Protein from FL83B cells was extracted by RIPA
buffer (Merck & Co., Inc., Kenilworth, NJ, USA), and
samples were then mixed with Laemmli buffer and
boiled at 95 C for 10 min. The 10% homogenates of
tissue samples were also made with RIPA lysis
buffer (Merck & Co.) with proteinase inhibitor
cocktail (cOmplete™, mini, EDTA-free Protease inhibitor cocktail, Roche, Basel, Switzerland) via
MiniBeadBeater-16 (BioSpec Products Inc., Bartlesville, OK, USA). The following procedure was done
as described in Chang et al [18]. Densitometry analyses were performed by using Image Lab software

Table 1. Growth performance, organ and fat-pad weights, serum biochemical values, hepatic antioxidative capacity, and hepatic pro-inﬂammatory
cytokines of experimental mice.
Growth performance
Initial body weight (g)
Final body weight (g)
Body weight gain (g)
Feed intake (g/mouse/day)
Water intake (mL/mouse/day)
Energy intake (kcal/mouse/day)
Feed efﬁciency (g WG/g diet)
Organ weights
Heart (g)
Liver (g)
Kidney (g)
Abdominal fat (g)
Blood biochemical values
TG (mg/dL)
TC (mg/dL)
AST (U/L)
ALT (U/L)
ALP (U/L)
Albumin (g/dL)
Ketone body (mg/dL)
Fasted glucose (mg/dL)
Free fatty acid (mmol/L)
Hepatic antioxidative capacities
TBARS (nmole MDA eq./mg protein)
Reduced GSH (nmole/mg protein)
TEAC (nmole/mg protein)
SOD (unit/mg protein)
CAT (unit/mg protein)
GPx (unit/mg protein)
Hepatic pro-inﬂammatory cytokines
TNF-a (pg/mg protein)
IL-1b (pg/mg protein)

Control

CLH

HFD

HFD þ CLHL

HFD þ CLHH

25.32 ± 0.56a
36.21 ± 1.48c
10.89 ± 0.99c
2.23 ± 0.03b
4.42 ± 0.19a
8.58 ± 0.13c
0.04 ± 0.00c

25.66 ± 0.61a
36.88 ± 0.63c
11.22 ± 0.48c
2.32 ± 0.03a
4.24 ± 0.12a
8.94 ± 0.12bc
0.04 ± 0.00c

25.48 ± 0.86a
53.30 ± 0.80a
27.82 ± 0.71a
1.95 ± 0.01c
3.37 ± 0.10b
9.43 ± 0.03a
0.11 ± 0.00a

25.29 ± 0.76a
49.44 ± 1.12b
24.14 ± 0.48b
1.92 ± 0.04c
3.56 ± 0.02b
9.30 ± 0.19ab
0.09 ± 0.00b

24.54 ± 0.71a
48.48 ± 0.72b
23.94 ± 0.46b
1.93 ± 0.02c
3.70 ± 0.10b
9.36 ± 0.10a
0.09 ± 0.00b

0.17
1.28
0.33
2.23

±
±
±
±

0.01a
0.05b
0.01b
0.10b

0.17
1.27
0.33
2.37

±
±
±
±

0.01a
0.02b
0.00b
0.19b

0.17
1.97
0.36
4.09

±
±
±
±

±
±
±
±

0.01a
0.20ab
0.01a
0.14a

0.17
1.51
0.36
4.17

±
±
±
±

0.00a
0.17a
0.01a
0.13a

0.17
1.60
0.36
4.02

0.01a
0.10b
0.01a
0.26a

± 16.79a
± 23.84a
± 9.84a
± 18.84a
± 3.01a
0.06a
0.16b
± 8.23a
0.01a

231.00 ± 25.60b
216.38 ± 27.42ab
136.88 ± 4.98ab
77.38 ± 11.51ab
272.63 ± 3.28c
3.18 ± 0.04a
6.28 ± 0.17b
152.63 ± 7.27bc
0.80 ± 0.05c

245.50 ± 17.94b
198.38 ± 23.72b
126.00 ± 14.24b
64.63 ± 7.44bc
248.88 ± 7.72d
3.11 ± 0.08a
6.47 ± 0.11ab
171.88 ± 12.61ab
0.80 ± 0.03c

172.63 ± 17.14c
187.38 ± 10.64b
97.50 ± 6.13c
51.50 ± 4.00bc
299.50 ± 4.26b
3.21 ± 0.06a
6.22 ± 0.20b
126.00 ± 4.44d
0.55 ± 0.02d

173.88 ± 5.20c
197.63 ± 6.89b
79.00 ± 4.09c
44.88 ± 2.42c
297.13 ± 2.80b
3.24 ± 0.05a
6.86 ± 0.03a
135.00 ± 3.25cd
0.92 ± 0.02b

322.38
271.25
159.63
103.38
319.63
3.16 ±
6.15 ±
184.13
1.13 ±

0.88 ± 0.02b
26.29 ± 1.46a
127.72 ± 2.17ab
6.51 ± 0.22b
36.33 ± 3.75ab
26.20 ± 1.60a

0.70 ± 0.04b
29.41 ± 1.42a
136.68 ± 7.25a
8.74 ± 0.16a
29.76 ± 1.55abc
26.55 ± 1.42a

1.47 ± 0.13a
29.08 ± 1.99a
110.62 ± 2.64c
2.70 ± 0.32d
28.00 ± 1.84c
16.34 ± 1.30b

0.78 ± 0.05b
28.41 ± 2.15a
121.76 ± 3.27bc
4.75 ± 0.48c
36.43 ± 2.72a
25.35 ± 0.99a

0.73 ± 0.04b
29.38 ± 3.34a
117.34 ± 1.76bc
5.43 ± 0.31c
29.37 ± 1.68bc
23.11 ± 2.66a

16.35 ± 0.91c
131.95 ± 7.03b

20.56 ± 0.88bc
123.74 ± 7.18b

35.37 ± 3.07a
200.28 ± 12.36a

20.52 ± 1.67bc
139.42 ± 7.69b

25.19 ± 2.26b
121.95 ± 11.75b

*The data are given as mean ± SEM (n ¼ 8, except feed, water, and energy intake, and feed efﬁciency, n ¼ 4). Mean values in each test
parameter without a common letter are signiﬁcantly different ( p < 0.05).
**All mice were randomly assigned to one of following groups: (1) Control group: basal diet; (2) CLH group: basal diet and CLHs; (3)
HFD group, high-fat diet (HFD, fat: 46.5% of caloric); (4) HFD þ CLHL group: HFD and CLHs (appr. 170 mg/kg BW); (5) HFD þ CLHH
group: HFD and CLHs (appr. 510 mg/kg BW).

(BioRad). The relative optical density of protein
bands was normalized with the b-Tubulin band. The
information of antibodies used in this study was
shown in Suppl. Table 1.
2.6. Animals and diets
The animal use and protocol were reviewed and
approved by the National Taiwan University Care
Committee (IACUC No.: NTU106-EL-00093). Forty
male 8-week-old C57BL/6 mice were purchased
from the Laboratory Animal Center of National
Taiwan University. The animal house's environmental parameters were as follows: temperature, 22
± 2 C, and light/dark cycle, 12/12 h. All mice were
randomly assigned to one of the following groups (n
¼ 8 per group): (1) Control group: basal diet; (2)
CLH group: basal diet and CLHs; (3) HFD group,
high-fat diet (HFD, fat: 46.5% of caloric); (4) HFD þ
CLHL group: HFD and CLHs (appr. 170 mg/kg BW);
(5) HFD þ CLHH group: HFD and CLHs (appr. 510
mg/kg BW). Two mice with an ear-tag (NO. 1 or 2)
were housed in one cage. The AIN-93M formulabased diet was prepared and served, and CLHs
were mixed with basal feed ingredients according to
our previous study within the 20-week experimental
period [21].
2.7. Collection of serum, liver, abdominal fat, feces,
and muscle of experimental mice
Blood was collected from each mouse at the end of
the experiment. At the end of the investigation, all
mice were weighed and fasted for 8 h and then
sacriﬁced by CO2 asphyxiation. Blood samples were
collected by orbital sinus and kept at room temperature for one h. Sera were obtained after
centrifugation (Model# 3700, Kubota Co., Tokyo,
Japan) at 3000g and 4 C for 10 min. The organ
tissues of each mouse were removed, weighed, and
recorded individually. The one-third dominant lobe
of the liver of each mouse was placed into a 10%
formaldehyde solution for histological analyses, and
other remnants, peri-renal adipose tissues, and right
or left hindlimb skeletal muscle from thigh to ankle
were immediately immersed in liquid N2 and then
stored at 80 C for the following analyses.
2.8. Serum biochemical values and lipid proﬁles of
livers and feces
Serum TG, TC, aspartate aminotransferase (AST),
ALT, alkaline phosphatase (ALP), albumin, ketone
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body (KB), FFA, and fasted glucose was assayed by
using an auto biochemistry analyzer (TBA 120FR
TOSHIBA Chemistry Analyzer, Toshiba Technology, Tokyo, Japan) and their corresponding kits.
Liver and fecal lipids were extracted according to
the previous study [22]. The Folch's extraction procedure was used, and the extracts were dried under
N2 and resuspended in isopropanol. Overall, TC
and TG concentrations were measured by using
commercial kits (Randox Laboratories Ltd., Antrim,
UK).
2.9. Hepatic lipid peroxidation and proinﬂammatory cytokine levels
Hepatic levels of thiobarbituric acid reactive substance (TBARS), reduced glutathione (GSH), and
trolox equivalent antioxidative capacity (TEAC), as
well as superoxide dismutase (SOD), catalase (CAT),
and glutathione peroxidase (GPx) activities were
assayed according to previously described methods
from Chen et al [23]. The hepatic tumor necrosis
factor (TNF)-a and interleukin (IL)-1b levels were
measured using an enzyme-linked immunosorbent
assay (ELISA) and conducted according to the
commercial manufacturer's instructions (TNF-a,
BioLegend, Inc., San Diego, CA, USA; IL-1b, R&D
system, Minneapolis, MN, USA).
2.10. Histological analyses and
immunohistochemistry stain of livers
All tissue blocks, slides, and stains (H&E and
Sirius red stain) were prepared according to the
methods described in our previous study [23]. The
blank liver slides were divided according to the
number of the ear tag in each cage (NO. 1 and NO.
2). In contrast, immunohistochemistry stain (IHC)
and Sirius red stains of livers were conducted with
those of NO. 1 and NO. 2 mice per cage, respectively. However, the analysis was observed and
graded via a visual inspection by the veterinarian
based on a report by Dixon, Bhathal, Hughes, and
O'Brien [24]. The quantiﬁcation of redness in Sirus
red-stained slides of the liver tissue (40) was also
analyzed using ImageJ (National Institutes of
Health, Bethesda, MD, USA). The minimum and
maximum thresholds were given as 145/168. For an
IHC analysis, the heat-induced epitope retrieval was
conducted, and tissue sections were incubated with
hydrogen peroxide block (TA-060-HP; ThermoFisher, Waltham, MA, USA) and protein block solution (TA-060-PBQ; ThermoFisher). Primary

ORIGINAL ARTICLE

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:375e388

380

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:375e388

ORIGINAL ARTICLE

antibody DGAT2 (ab237613, Abcam; 100  dilution)
and ACDAM (ab92461, Abcam; 100  dilution) were
used for 40 min incubation in a humidiﬁed chamber. Next, tissue sections were treated with rabbit
antibody enhancer (D39; Golden Bridge International, Inc., Bothell, WA, USA) and polymer-HRP
for rabbit (D39; Golden Bridge International, Inc.),
respectively. The DAB peroxidase substrate (TA060-QHSX and TA-002-QHCX; ThermoFisher) was
used. The microscopic analysis was conducted via
Leica DM500 microscope (Leica Microscope,
Singapore) with Toup View 3.7 software (Toup Tek
Co., LTD, Hangzhou, China).
2.11. Intraperitoneal glucose tolerance test
The intraperitoneal glucose tolerance test (ipGTT)
was conducted in the 20th week of the experimental
period. All mice were fasted for 8 h before a glucose
(2 g/kg BW) intraperitoneal injection. Then blood
samples were collected via the facial vein sampling
method. The sensitivity of blood glucose monitor
(GM300, Bionime Corp., Taichung, Taiwan) is from
10 to 600 mg/dL. The area under the curve (AUC)
was calculated from the sampling period of 0 to 120
min. The procedure was according to Andrikopoulos et al. [25].

2.12. Statistical analysis
The experiment was conducted by using a
completely randomized design. When a signiﬁcant
difference ( p < 0.05) among groups was detected
using the one-way analysis of variance (ANOVA),
differences between treatments were further distinguished using the least signiﬁcant difference (LSD)
test. All statistical analyses of data were conducted
via SAS (SAS Institute Inc., Cary, NC, USA, 2002).

3. Results
3.1. Effects of CLHs on OA-induced lipid
accumulation in vitro
The short- and long-term impacts of CLHs on the
survivability of FL83B cells in FBS containing culture
system were determined (Fig. 1A). There were
almost no differences among tested CLH levels for 6
h; on the contrary, the cell survival ratio for 12-h
treatment in the FBS culture system was decreased
( p < 0.05) beyond 500 mg CLH/L. Because the OA
12-h incubation was successfully proven to enhance
cellular steatosis, the 12-h incubation was chosen in
the following procedure. Next, the optimal concentration range of CLHs or OA used in the following
assays were determined in the FBS-free culture

Fig. 2. Effects of CLHs on target protein expressions in the OA-induced FL83B cells. (A) The illustration of protein expressions related to fatty-acid
synthesis (pAMPK/AMPK, ACC, and FAS) and energy expenditure (PPARa, CPT1, and UCP2) under OA and CLH intervention. (B) The quantiﬁcation results of western blotting, including proteins related to fatty acid synthesis and energy expenditure. The data are given as mean ± SEM (n ¼
8). Data bars in each target protein without a common letter are signiﬁcantly different ( p < 0.05).
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Fig. 3. The pathohistological analyses in liver tissues, hepatic lipid, fecal lipid/bile acid proﬁles, ipGTT, and protein expressions in the liver, skeletal
muscle, and peri-renal fat tissues of experimental mice. (A) Appearances, and H&E and Sirius red stain of liver tissues were shown. The histological
photomicrographs were displayed with 100  magniﬁcation. The scale bar was established in the bottom right corner of each image. The yellow and
green arrowheads indicate macrosteatosis and microsteatosis, respectively, and the black arrowheads indicate the ﬁbrotic scar. CV means a central
vein. (B) The quantiﬁcation was conducted via the respective histological grading system. The data are given as mean ± SEM (n ¼ 8 for H&E stain; n
¼ 4 for Sirius red stain). Data bars in steatosis or ﬁbrotic scores without a common letter are signiﬁcantly different ( p < 0.05). (C) Hepatic lipid and
fecal lipid/bile acid of experimental mice at the end of the experiment. The data are given as mean ± SEM (n ¼ 8). Data bars in each test parameter
without a common letter are signiﬁcantly different ( p < 0.05). (D) The glucose tolerance test was conducted via intraperitoneal injection. The AUC
was calculated, and the results were shown via the bar chart. Data are given as mean ± SEM (n ¼ 8). Data points of each time point and bars of AUC
without a common letter are signiﬁcantly different, respectively ( p < 0.05). (E) The illustration and quantiﬁcation of proteins related to insulin signals
in the liver, skeletal muscle, and peri-renal fat tissues, respectively. The data are given as mean ± SEM (n ¼ 8). Data bars in each target protein
without a common letter are signiﬁcantly different ( p < 0.05).
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system. The cell survival ratio was increased ( p <
0.05) under 10 mg CLH/L addition but decreased ( p
< 0.05) since an addition was higher than 20 mg
CLH/L (Fig. 1B). Meanwhile, the cellular LDH
leakage was elevated ( p < 0.05) beyond 1,000 mg
CLH/L addition (Fig. 1B). Besides, no ( p > 0.05)
differences in either cell survival ratio or LDH
leakage were detected under the tested OA concentrations (0 to 400 mM, Fig. 1C). Fig. 1D showed
that the intracellular lipid accumulation was significantly induced ( p < 0.05), while OA concentration
exceeded 100 mM. More lipid accumulation was
observed in the 400 mM OA induction via the Oil red
O stain (Fig. 1E). Furthermore, an increase of
cellular lipid accumulation by a 400 mM-OA induction was attenuated ( p > 0.05) by CLH treatments,
and the largest reduction was shown at 4 mg CLH/L
addition (Fig. 1F). According to the protein expressions related to fatty-acid synthesis and fatty-acid b
oxidation (Fig. 2B), the downregulations ( p < 0.05) of
AMP-activated protein kinase phosphorylation
(pAMPK/AMPK), peroxisome proliferator-activated
receptor a (PPARa), and carnitine palmitoyltransferase 1 (CPT1), as well as upregulations ( p <
0.05) of acetyl-CoA carboxylase (ACC), fatty acid
synthase (FAS), and uncoupling protein 2 (UCP2)
were assayed in the OA induction. However, the
decrease of pAMPK/AMPK, as well as increases of
ACC and FAS expressions by OA induction, were
reversed ( p < 0.05) by CLH treatment; meanwhile,
PPARa, CPT1, and UCP2 expressions were upregulated ( p < 0.05) (Fig. 2B).
3.2. Effects of CLHs on physiological parameters,
blood biochemical values, hepatic antioxidative
capacities, and pro-inﬂammatory cytokines of
experimental mice
Increased ﬁnal body weights, body weight gains,
and feed efﬁciencies by the HFD feeding were
decreased ( p < 0.05) by CLH supplementation, but
there was no ( p > 0.05) difference in feed intakes
among HFD and CLH-cotreated groups (HFD þ
CLHL and HFD þ CLHH groups) (Table 1). Regarding
blood biochemical values (Table 1), serum TG, TC,
FFA, AST, ALT, and ALP were elevated ( p < 0.05)
under the HFD feeding but amended ( p < 0.05) by
supplementing with CLHs. Serum albumin levels
were not ( p > 0.05) inﬂuenced. Still, the serum ketone
body (KB) of the CLH group was higher ( p < 0.05) than
that of other groups. Liver TBARS values in the HFD
group were higher ( p < 0.05) than those of control dietfed groups (Control and CLH groups) but decreased

( p < 0.05) in CLH cotreated mice. Although there were
no ( p > 0.05) difference in reduced GSH contents in
livers among groups, liver TEAC values, and SOD,
CAT, and GPx activities in the HFD group were lower
( p < 0.05) than those of control diet-fed groups.
However, those values in HFD-fed mice were
strengthened ( p < 0.05) by CLH intervention.
Furthermore, the higher ( p < 0.05) hepatic pro-inﬂammatory cytokines (TNF-a and IL-1b) due to the
HFD feeding were improved ( p < 0.05) by supplementing with CLHs.
3.3. Effects of CLHs on hepatic steatosis and insulin
resistance of liver, adipose tissue, and skeletal
muscle
Results of H&E stains revealed the morphology
of hepatosteatosis in livers of HFD-fed mice and
fewer lipid droplets in CLH cotreated mice (Fig.
3A). Similarly, the steatosis score of the HFD group
was higher ( p < 0.05) than that of other groups
(Fig. 3B), and the HFD-induced increases of liver
TG contents were also decreased by supplementing with CLHs ( p < 0.05; Fig. 3C). Increased ( p <
0.05) fecal lipid and bile-acid contents were
measured in HFD-fed mice than control-diet fed
mice, but there were tendencies toward higher
fecal TG and TC contents in CLH cotreated groups
rather than HFD group (Fig. 3C). Furthermore,
Sirius red-stained photos indicated that the more
ﬁbrotic scars in livers of HFD-fed mice were
diminished by supplementing with CLHs (Fig. 3A).
The results of ﬁbrotic scores were corresponding
to them (Fig. 3B). According to Fig. 3D, the blood
glucose levels of the HFD group were the highest
( p < 0.05) from 30 to 120 min after a glucose i.p.
injection among groups, and the increased ( p <
0.05) AUC of HFD-fed mice was decreased ( p <
0.05) by supplementing with CLHs. Similarly, the
higher ( p < 0.05) fasted serum glucose values of
HFD-fed mice were observed than those of control-diet fed mice but decreased by supplementing
with CLHs (HFD þ CLHL vs. HFD, p < 0.05) (Table
1). The protein expressions of insulin receptor b
(IRb) in both liver and skeletal muscle were
upregulated ( p < 0.05) by the HFD feeding but
downregulated ( p < 0.05) by supplementing with
CLHs (Fig. 3E). Regarding the glucose transportation in the organs (Fig. 3E), no ( p < 0.05)
differences of Glucose transporter type 4 (GLUT4)
protein expressions in the liver, skeletal muscle,
and peri-renal fat tissues among the HFD group
and control-diet fed groups, but GLUT4
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Fig. 4. Immunohistochemical analyses in the liver of experimental mice. (A) DGAT2 and (B) ACADM protein expressions were IHC analyzed.
DGAT2 is the last major enzyme for converting diacylglycerol to TG; whereas, ACADM is the crucial enzyme in fatty-acid b oxidation. Histological
photomicrographs were shown at 40  , 100  , and 400  magniﬁcations, respectively. The red arrows indicate a positive area, while the black
arrowheads indicate the central vein (CV). Liver sections were examined with primary antibody (except negative control, NC) and hematoxylin
stained.

expressions in HFD-fed mice were increased ( p <
0.05) multiple times via supplementing with CLHs
(Fig. 3E). Next, the HFD feeding resulted in more
DGAT2 protein expressions in livers; however,
CLH supplementation diminished the positively
stained area (Fig. 4A). Besides, the CLH-induced
increase of ACADM protein amounts was
observed in HFD cotreated mice rather than those
without CLHs (Fig. 4B).

4. Discussion
According to the proximate analysis of CLHs, the
major components were 69.57% protein and 22.93%
ash (Suppl. Table 2). There were many kinds of free
amino acids and anserine (imidazole-ring dipeptide)
in CLHs [e.g., L-lysine, branched-chain amino acids
[BCAAs, valine (Val), leucine (Leu), and isoleucine
(Ile)], b-alanine (a precursor of carnosine), L-aspartic
acid, glycine, L-ornithine, taurine, and anserine]
(Suppl. Table 2). Moreover, the amount of BCAAs
(1800 mg/100g CLHs) was consistent in CLHs to be
regarded as the quality control index for further
CLH manufacturing.
The in vitro experiment was designed to simulate
the long-term HFD exposure, and the cell model of

the OA-induced hepatocyte steatosis which could
interpret the in vivo ﬁndings was well built [9, 16,
26]. According to D'Antona et al., plasma peak
concentrations after a bolus administration of
isoleucine, leucine, and valine were revealed as
750, 2000, and 1800 pmole/mL, respectively, and the
value was helpful to determine the physiological
meanings in a cell model [27]. After conversion,
the 40 mg CLHs (Ile, Leu, and Val were 380.54,
831.75, and 626.49 mg/100g CLHs, Suppl. Table 2)
in a one-L medium would simulate the portal vein
BCAA concentration above proximately. However,
the cytotoxicity of CLHs was low because survival
ratios of FL83B cells were still about 80% even
though the treating concentrations were 100 times
(4000 mg CLHs/L) than in vivo concentration
reference (40 mg CLHs/L eq.) (Fig. 1A). Moreover,
Fig. 1F indicated that the effective treating concentration of CLHs at 2 to 8 mg/L could decrease
the lipid accumulation in OA-treated FL83B cells.
It was less than the in vivo concentration reference
(40 mg CLHs/L eq.). Therefore, the effects of CLHs
was not only nutritional but also bio-functional.
The lipid droplets were found under OA treatment, and the protein expression pattern of fattyacid synthesis (ACC and FAS) was consistent with
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Fig. 5. The ameliorative effects of CLHs on insulin resistance, hepatic steatosis, hyperlipidemia, and obesity against a chronic HFD induction. The
HFD-induced metabolic disorders are indicated in the white zone. At the same time, the ameliorative effects of CLHs are shown in a grey zone.

the previous in vivo study (Fig. 2) [18]. The protein
regulating pattern results showed that CLHs could
attenuate the cellular steatosis directly via downregulating fatty-acid synthesis and upregulating

energy expenditure (Fig. 2). Moreover, the phosphorylation of AMPK, the upstream messenger of
cellular energy metabolism, was signiﬁcantly
increased in this study (Fig. 2), which contributed

to its downstream signal cascades [28]. Besides, the
AMPK activation improved hepatic steatosis in
most NAFLD studies [25, 29, 30].
The bio-functionalities of CLHs had been proven
due to BCAAs, taurine, acidic amino acid, and
anserine [2, 3, 21, 23, 30]. In this study, the CLHs could
decrease ( p < 0.05) body weight gains against the
long-term HFD (fat: 46.5 kcal%) induction in mice
(Table 1). In comparison with the previous results, the
disparity in those regulating patterns could be due to
the difference in the period of HFD-feeding intention
(8 weeks vs. 20 weeks) and rodent species (hamsters
vs. mice). Remarkably, the hypolipidemic effects of
CLHs were consistent (Table 1) [2]. Regarding
enhancing antioxidant capacities of HFD-fed mice
cotreated with CLHs (Table 1), the antioxidant effects
of CLH supplementation might be attributed to
imidazole ring molecules, b-alanine, hydrophobic
amino acids, and antioxidant minerals [31]. Moreover, the ameliorative effects of CLHs on increased
liver weights, pro-inﬂammatory cytokines (TNF-a
and IL-1b), and worse hepato-pathological analyses
HFD-fed mice were remarkable (Table 1 & Fig. 3).
There were 7/8 highly severe and 1/8 severe in the
HFD group, while only 3/8 highly severe in the CLHcotreated group (Suppl. Table 3), which showed the
pathohistological improvement under the CLH
intervention. Both results of hepatic steatosis and
ﬁbrotic scores apparently indicated the delay of the
hepatosteatosis progressing in HFD-fed mice
cotreated with CLHs (Fig. 3A and B). Moreover, the
biochemical blood markers related to liver damage,
such as AST, ALT, and ALP values in HFD-fed mice,
were decreased ( p < 0.05) by supplementing with
CLHs (Table 1). Furthermore, the highly expressed
DGAT2 in livers of HFD-fed mice was reduced by
supplementing with CLHs, which inferred that CLHs
could retard the TG formation and lipid deposition
(Fig. 3AeC & 4A). Moreover, the ACADM expressions in livers of HFD-fed mice were enhanced under
CLH cotreatment (Fig. 4B). Overall, in vivo ﬁndings
were consistent with the outcomes of the cell model
(Figs. 2 and 4). In the previous studies, the hepatoprotection of L-leucine, L-lysine, L-ornithine, and
L-aspartate in the manner of NAFLD had been
mentioned; meanwhile, those lipid-lowering free
amino acids (easily absorbed) existed in a plentiful
amount in CLHs (Suppl. Table 2) [32-34].
Hepatic and peripheral IR (mainly skeletal muscle
and white adipose tissue) were aggravated in all
forms of NAFLD progression, gaining the risk of
consecutive T2DM (Table 1) [6, 35]. For universal IR,
the higher concentration of circulating glucose and
FFA both stimulated an elevation of de novo lipogenesis (DNL) in the liver, which represents a key
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feature of NAFLD (Table 1 & Fig. 3A) [7]. In recent
reports, dietary leucine was considered a key player
in the insulin-sensitivity improvement, which might
also manipulate both the glucose and lipid metabolism while there was 831.75 ± 0.83 mg leucine per
100g CLHs (Suppl. Table 2) [15]. According to the
results (Fig. 3E), CLH supplementation sustained
the insulin signal sensitivity in skeletal muscle and
peri-renal fat tissues against the long-term HFD
feeding because of the downstream GLUT4
response to upstream insulin signal in CLH
cotreated mice compared to that of HFD group.
Kairupan et al. reported that expressions of GLUT4
were modulated by upstream AMPK signal in
skeletal muscle, which was consistent to our results
[36]. Graham et al. proposed that the amount of
GLUT4 in white adipose tissues represented a good
systemic insulin sensitivity marker [37]. These effects might also contribute to decreased fasted
serum glucose and FFA. Therefore, the DNL might
remain non-activated in hepatic tissue due to a lack
of external factors and resources. In vitro (ACC &
FAS) and in vivo (DGAT2) results in this study
conformed to this assumption (Figs. 2 & 4A).
Hepatosteatosis was aggravated because of the
loss of mitochondrial adaption [38, 39]. Since metabolic burdens of dietary fat exist, hepatic mitochondria transiently adapt to lipid availability
enhancement by upregulating their oxidative capacity at the expense of decreased coupling efﬁciency [39]. Loss of mitochondria adaptation caused
lipid overloading, oxidative stress, and inﬂammation, resulting in non-alcoholic steatohepatitis [7].
The results of ACADM expressions indicate that
CLH supplementation promoted mitochondrial
fatty-acid b oxidation. The CPT1 and UCP2 were
upregulated in CLH-treated cells (Figs. 2 & 4B),
which sustain the mitochondrial adaption. Likewise,
BCAAs (especially leucine) modulation on mitochondrial biogenesis and fatty-acid b oxidation
through the AMPK dependent pathway were
revealed [40]. Furthermore, the antioxidant effects of
CLHs had been mentioned [2, 21, 31]. In this study,
CLH supplementation also showed an increase of
antioxidant capacities and a decrease of inﬂammatory responses in livers of HFD-fed mice (Table 1).
Overall, mitochondrial adaption and function were
sustained via supplementing with CLHs.
The fatty-acid b oxidation was the crucial mitochondrial function in lipid metabolism. Its major
product was the b-hydroxybutyrate (a major
component of KB). In this study, CLH enhanced the
fatty-acid b oxidation ﬂux (Figs. 2 & 4B); remarkably,
the serum KB value of the CLH group was even
higher ( p < 0.05) than that of the Control group
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(Table 1). Although the universal IR would suppress
the fatty-acid b oxidation ﬂux, the CLH supplementation showed an increased tendency toward
serum KB with a dose-dependent effect (Table 1).
Moreover, the KB results correspond to the results
of ACADM expression (Table 1 & Fig. 4B). Xu et al.
proclaimed that ketogenic essential amino acids
(leucine and lysine) ameliorated hepatosteatosis;
meanwhile, diabetic ketoacidosis was crucial for
clinical diagnosis [41]. The serum b-hydroxybutyrate of diabetic mice could be elevated almost
10-times of those of normal mice (2 mg/dL vs. 19-20
mg/dL) [42, 43]. However, ketosis but no ketoacidosis in mice was observed under 20-week CLHsupplementation in this study.
In conclusion, bio-active free amino acids were a
major constituent of CLHs, including L-lysine,
BCAAs, b-alanine, L-aspartic acid, glycine, L-ornithine, and taurine, as well as anserine. Through the
OA-induced cellular steatosis and HFD-induced
mouse model, the attenuative effects of CLHs on
hepatic lipid deposition, hepatic/peripheral IR, and
oxidative stress have been elucidated (Fig. 5). CLH
supplementation could improve the universal
glucose homeostasis via sustaining hepatic and peripheral insulin sensitivities and improved lipid
dyshomeostasis to demonstrate anti-IR, anti-hepatosteatosis, and anti-obesity in various outcomes.
To sum up, this CLH development could not only
enhance the added value of broiler livers as the
nutraceutical ingredients in the niche market but
also decrease the environmental burden caused by
the broiler industry.
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Suppl. Table 2. Proximate analysis, free amino acid composition, and
imidazole-ring dipeptides of chicken-liver hydrolysates.
CLHs
Nutrient (per 100 gram)
Water (g)
Crude protein (g)
Crude fat (g)
Ash (g)
Amino acids (mg/100g dried weight)
L-Arginine
L-Histidine
L-Isoleucine
L-Leucine
L-Lysine
L-Methionine
L-Phenylalanine
L-Threonine
Tryptophan
L-Valine
Total EAA
Total BCAA
L-Alanine
b-Alanine
g-Aminobutyric acid
DL-3-Aminoisobutyric acid
Asparagine
L-Aspartic acid
L-Cystathionine
Ethanolamine
L-Glutamic acid
Glycine
DL-plus allo-d-Hydroxylysine
L-Hydroxyproline
L-Ornithine
O-phosphoserine
L-Proline
L-Serine
Taurine
L-Tyrosine
Total NEAA
L-Anserine
L-Carnosine
Imidazole-ring dipeptide

6.82 ± 0.09
69.57 ± 0.00
0.14 ± 0.01
22.93 ± 0.92
605.88 ± 10.50
196.64 ± 6.03
380.54 ± 20.53
831.75 ± 0.83
776.61 ± 7,57
295.15 ± 24.55
422.66 ± 52.78
470.95 ± 6.85
74.26 ± 4.00
626.49 ± 12.74
4680.92 ± 102.53
1838.78 ± 33.27
780.03 ± 4.37
31.73 ± 0.75
1.87 ± 0.00
23.23 ± 7.03
23.11 ± 2.59
710.31 ± 17.52
21.33 ± 1.92
18.60 ± 1.65
1400.50 ± 135.48
438.24 ± 3.96
5.81 ± 0.28
24.56 ± 1.04
36.84 ± 5.55
63.41 ± 6.11
612.19 ± 11.37
598.25 ± 9.79
301.09 ± 29.64
335.74 ± 16.89
5426.83 ± 184.35
123.79 ± 1.29
N.D.
123.79 ± 1.29

*EAA: essential amino acid; BCAA: branched-chain amino acid;
NEAA: non-essential amino acid; N. D.: not detectible.

Appendix A. Supplementary material
Suppl. Table 1. List of antibodies for western bolting in this study.
Target protein

Abbr. name

Brand

acetyl-CoA carboxylase
fatty acid synthase
AMP-activated protein kinase a
phosphorylated AMP-activated protein kinase a
carnitine palmitoyltransferase I
peroxisome proliferator-activated receptor a
uncoupling proteins 2
insulin receptor
glucose transporter type 4
b-Tubulin

ACC
FAS
AMPKa
p-AMPKa
CPT1
PPARa
UCP2
IRb
GLUT4
b-Tubulin

Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Millipore Co.
Abcam
Millipore Co.
Cell Signaling
Cell Signaling
Cell Signaling

Technology
Technology
Technology
Technology

Inc.
Inc.
Inc.
Inc.

Technology Inc.
Technology Inc.
Technology Inc.

Catalog NO.

Dilution

#3662
#3180
#2532
#2535
#ABS65
ab24509
#662047
#3025
#2213
#2128

1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000

References
[1] Council of Agriculture, Executive Yuan, Taiwan. Agricultural
Production: 2. Livestock Production; 2020. Available at
https://eng.coa.gov.tw/ws.php?id¼2505611. [Accessed 17
November 2020].
[2] Yang KT, Lin C, Liu CW, Chen YC. Effects of chicken-liver
hydrolysates on lipid metabolism in a high-fat diet. Food
Chem 2014;160:148e56.
[3] Lin YL, Tai SY, Chen JW, Chou CH, Fu SG, Chen YC.
Ameliorative effects of pepsin-digested chicken liver hydrolysates on development of alcoholic fatty livers in mice.
Food Funct 2017;8:1763e74.
[4] Chen YC, Chen PJ, Tai SY. National Taiwan University,
US10105; 2018, 400B2.
[5] International Diabetes Federation (IDF). Global picture. IDF
diabetes atlas. 9th ed. Brussels, Belgium: IDF; 2019.
[6] Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi
E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD)
and its connection with insulin resistance, dyslipidemia,
atherosclerosis and coronary heart disease. Nutrients 2013;5:
1544e60.
[7] Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol 2017;14:32e42.
[8] European Association for the Study of the Liver (EASL),
European Association for the Study of Diabetes (EASD),
European Association for the Study of Obesity (EASO).
EASL-EASD-EASO Clinical Practice Guidelines for the
management of non-alcoholic fatty liver disease. J Hepatol
2016;64:1388e402.
[9] Liu Y, Wang D, Zhang D, Lv Y, Wei Y, Wu W, et al. Inhibitory effect of blueberry polyphenolic compounds on oleic
acid-induced hepatic steatosis in vitro. J Agric Food Chem
2011;59:12254e63.
[10] Drummond E, Flynn S, Whelan H, Nongonierma AB, Holton
TA, Robinson A, et al. Casein hydrolysate with glycemic
control properties: Evidence from cells, animal models, and
humans. J Agric Food Chem 2018;66:4352e63.
[11] Yang Y, Wang J, Zhang Y, Li J, Sun W. Black sesame seeds
ethanol extract ameliorates hepatic lipid accumulation,
oxidative stress, and insulin resistance in fructose-induced
nonalcoholic fatty liver disease. J Agric Food Chem 2018;66:
10458e69.
[12] Sulochana KN, Punitham R, Ramakrishnan S. Beneﬁcial effect of lysine and amino acids on cataractogenesis in experimental diabetes through possible antiglycation of lens
proteins. Exp Eye Res 1998;67:597e601.
[13] Li W, Zhang Y, Shao N. Protective effect of glycine
in streptozotocin-induced diabetic cataract through reductase inhibitory activity. Biomed Pharmacother 2019;114:
108794.
[14] Nandhini AT, Thirunavukkarasu V, Anuradha CV. Taurine
prevents collagen abnormalities in high fructose-fed rats.
Indian J Med Res 2005;122:171e7.
[15] Bruckbauer A, Zemel MB, Thorpe T, Akula MR, Stuckey AC,
Osborne D, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes
and mice. Nutr Metab 2012;9:77.
[16] Chang JJ, Hsu MJ, Huang HP, Chung DJ, Chang YC, Wang
CJ. Mulberry anthocyanins inhibit oleic acid-induced lipid
accumulation by reduction of lipogenesis and promotion of
hepatic lipid clearance. J Agric Food Chem 2013;61:6069e76.
[17] Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate ﬂux. J
Clin Investig 2016;126:12e22.
[18] Chang R, Chou MC, Hung LY, Wang ME, Hsu MC, Chiu
CH. Study of valproic acid-enhanced hepatocyte steatosis.
Biomed Res Int 2016;2016:9576503.
[19] Lau JKC, Zhang X, Yu J. Animal models of non-alcoholic
fatty liver disease: current perspectives and recent advances.
J Pathol 2017;241:36e44.

387

[20] Association of Ofﬁcial Analytical Chemists (AOAC). Ofﬁcial
Methods of Analysis. 2005. Arlington, VA, USA.
[21] Wu YS, Lin YL, Huang C, Chiu CH, Nakthong S, Chen YC.
Cardiac protection of functional chicken-liver hydrolysates
on the high-fat diet-induced cardio-renal damages via sustaining autophagy homeostasis. J Sci Food Agric 2020;100:
2443e52.
[22] Chang YY, Lin YL, Yang DJ, Liu CW, Hsu CL, Tzang BS, et
al. Hepatoprotection of noni juice against chronic alcohol
consumption: Lipid homeostasis, antioxidation, alcohol
clearance, and anti-inﬂammation. J Agric Food Chem 2013;
61:11016e24.
[23] Chen PJ, Tseng JK, Lin YL, Wu YS, Hsiao YT, Chen JW, et al.
Protective effects of functional chicken liver hydrolysates
against liver ﬁbrogenesis: antioxidation, anti-inﬂammation,
and antiﬁbrosis. J Agric Food Chem 2017;65:4961e9.
[24] Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic
fatty liver disease: Improvement in liver histological analysis
with weight loss. Hepatology 2004;39:1647e54.
[25] Andrikopoulos S, Blair AR, Deluca N, Fam C, Proietto J.
Evaluating the glucose tolerance test in mice. Am J Physiol
Endocrinol Metab 2008;295:E1323e32.
[26] Chen JW, Kong ZL, Tsai ML, Lo CY, Ho CT, Lai CS. Tetrahydrocurcumin ameliorates free fatty acid-induced hepatic
steatosis and improves insulin resistance in HepG2 cells. J
Food Drug Anal 2018;26:1075e85.
[27] D'Antona G, Ragni M, Cardile A, Tedesco L, Dossena M,
Bruttini F, et al. Branched-chain amino acid supplementation
promotes survival and supports cardiac and skeletal muscle
mitochondrial biogenesis in middle-aged mice. Cell Metab
2010;12:362e72.
[28] Peng X, Li J, Wang M, Qu K, Zhu H. A novel AMPK activator
improves hepatic lipid metabolism and leukocyte trafﬁcking
in experimental hepatic steatosis. J Pharmacol Sci 2019;140:
153e61.
[29] Yang TH, Yao HT, Chiang MT. Red algae (Gelidum amansii)
got-water extract ameliorates lipid metabolism in hamsters
fed a high-fat diet. J Food Drug Anal 2017;25:931e8.
[30] Tung YC, Liang ZR, Chou SF, Ho CT, Kuo YL, Cheng KC, et
al. Fermented soy paste alleviates lipid accumulation in the
liver by regulating the AMPK pathway and modulating gut
microbiota in high-fat-diet-fed rats. J Agric Food Chem 2020;
68:9345e57.
[31] Chou CH, Wang SY, Lin YT, Chen YC. Antioxidant activities
of chicken liver hydrolysates by pepsin treatment. Int J Food
Sci Technol 2014;49:1654e62.
[32] Lin HY, Chen CC, Chen YJ, Lin YY, Mersmann HJ, Ding ST.
Enhanced amelioration of high-fat diet-induced fatty liver by
docosahexaenoic acid and lysine supplementations. Biomed
Res Int 2014;2014:310981.
[33] Pedroso JA, Zampieri TT, JJr Donato. Reviewing the effects of
L-leucine supplementation in the regulation of food intake,
energy balance, and glucose homeostasis. Nutrients 2015;7:
3914e37.
[34] Butterworth RF, Canbay A. Hepatoprotection by L-ornithine
L-aspartate in non-alcoholic fatty liver disease. Dig Dis 2019;
37:63e8.
[35] Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader
M, Baldi S, et al. Insulin resistance in non-diabetic patients
with non-alcoholic fatty liver disease: sites and mechanisms.
Diabetologia 2005;48:634e42.
[36] Kairupan TS, Cheng KC, Asakawa A, Amitani H, Yagi T,
Ataka K, et al. Rubiscolin-6 activates opioid receptors to
enhance glucose uptake in skeletal muscle. J Food Drug Anal
2019;27:266e74.
[37] Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP,
Henry RR, et al. Retinol-binding protein 4 and insulin
resistance in lean, obese, and diabetic subjects. N Engl J Med
2006;354:2552e63.
[38] Li Z, Li Y, Zhang HX, Guo JR, Lam C, Wang CY, et al.
Mitochondria-mediated pathogenesis and therapeutics for
non-alcoholic fatty liver disease. Mol Nutr Food Res 2019;63:
e1900043.

ORIGINAL ARTICLE

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:375e388

388

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:375e388

ORIGINAL ARTICLE

[39] Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, et al. Adaptation of hepatic mitochondrial function in
humans with non-alcoholic fatty liver is lost in steatohepatitis.
Cell Metab 2015;21:739e46.
[40] Sun X, Zemel MB. Leucine modulation of mitochondrial
mass and oxygen consumption in skeletal muscle cells and
adipocytes. Nutr Metab 2009;6:26.
[41] Xu L, Kanasaki M, He J, Kitada M, Nagao K, Jinzu H, et al.
Ketogenic essential amino acids replacement diet ameliorated hepatosteatosis with altering autophagy-associated
molecules. Biochim Biophys Acta 2013;1832:1605e12.

[42] Denroche HC, Levi J, Wideman RD, Sequeira RM, Huynh
FK, Covey SD, et al. Leptin therapy reverses hyperglycemia
in mice with streptozotocin-induced diabetes, independent
of hepatic leptin signaling. Diabetes 2011;60:1414e23.
[43] Trak-Smayra V, Paradis V, Massart J, Nasser S, Jebara V,
Fromenty B. Pathology of the liver in obese and diabetic ob/
ob and db/db mice fed a standard or high-calorie diet. Int J
Exp Pathol 2011;92:413e21.

